
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics Inc. is focused on developing innovative precision oncology therapies, particularly with its two MTA-cooperative PRMT5 inhibitors, TNG462 for non-CNS cancers and TNG456 for CNS cancers, which positions the company favorably within the biotech sector. With a market capitalization of approximately $400 million and about $300 million in cash, the company is well-capitalized to support the next stages of development for TNG462, which could significantly enhance its stock value if it generates compelling data. Additionally, the promising early results from their therapeutic combinations and the ongoing progression of TNG456 highlight the potential for deeper and more frequent regressions in target cancer models, supporting a positive outlook for the company’s future performance.
Bears say
Tango Therapeutics Inc faces significant risks that could adversely impact its stock performance and market competitiveness, primarily stemming from its lead assets, TNG908 and TNG462, which may yield negative clinical results or experience delays in their advancement into registrational programs. Furthermore, the company contends with heightened competitive pressures from other clinical-stage PRMT5 inhibitors and a potential inability to secure timely regulatory approvals, which could hinder its commercialization efforts. Lastly, the noted long-term dilution risk and the lackluster stock recovery following recent adverse news contribute to a negative overall outlook for the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares